Fig. 3: Sub-chronic ketamine reduces parvalbumin interneuron function. | Molecular Psychiatry

Fig. 3: Sub-chronic ketamine reduces parvalbumin interneuron function.

From: Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine

Fig. 3

a Schematics of the location of the PLc and vSub of the hippocampus in the brain. Representative fluorescence confocal images of  PLc and vSub of the hippocampus fields respectively depicting PV interneuron (green) and DAPI (blue) immunofluorescence in saline-treated (Saline) and ketamine-treated (Ketamine) mice. PV immunofluorescence in the PLc and vSub of the hippocampus is significantly reduced in the ketamine versus saline group (Two-way repeated-measures ANOVA significant effect of treatment, F1, 8 = 47.28, p < 0.001, η2 effect size = 0.86; followed by Bonferroni post hoc tests (P < 0.05); n = 5 mice per group). b Differential expression of the PV gene in ketamine-treated mice vs. saline treated controls. Differential expression of RASGRP2 and MAPK3 genes in ketamine-treated mice vs. saline treated controls. Log2 fold change is shown in each respective bar. c Increased activity in the calcium signalling and cAMP-mediated signalling pathways in ketamine-treated vs. control group. Data represent mean ± S.E.M. *P < 0.05. PLc pre-limbic cortex, vSub ventral subiculum of the hippocampus, PV parvalbumin.

Back to article page